ABSTRACT
174MMP-2 and MMP-9 are involved in the pathogenesis of diabetic complications. Thus, targeting MMP-2 and MMP-9 over expression in diabetes can be a treatment strategy for the vascular complications of diabetes. Recently there is an emerging interest in the design and synthesis of MMP inhibitors. Many molecules have reached clinical trials but not many molecules under study have shown promising results which may be due to associated toxicity. Naturally occurring MMP-2 and MMP-9 inhibitors are providing alternatives to synthetic molecule with less toxicity. This chapter discusses efficacy of Nobiletin, a polymethoxyflavone, in the treatment of diabetic complications.
